📊 PROK Key Takeaways
Is Prokidney Corp.. (PROK) a Good Investment?
ProKidney Corp exhibits severe financial distress with negative stockholders' equity (-$1.0B), massive operating losses (-$165M on $893K revenue), and unsustainable cash burn (-$135.3M FCF). With current cash reserves (~$108.5M) and burn rate exceeding $135M annually, the company faces insolvency within 12 months unless it achieves significant revenue acceleration or obtains additional financing.
Why Buy Prokidney Corp.. Stock? PROK Key Strengths
- Strong revenue growth rate (+1075% YoY, though from minimal base)
- Net loss improving substantially YoY (+54.5% improvement)
- Adequate short-term liquidity with $108.5M cash and 9.13x current ratio
PROK Stock Risks: Prokidney Corp.. Investment Risks
- Negative stockholders' equity indicating technical insolvency on book value basis
- Catastrophic burn rate: -$135.3M free cash flow annually with <1 year cash runway
- Operating margin of -18477.8% demonstrates business model is severely unprofitable at current scale
- Minimal revenue generation relative to operating expenses indicates early/failed commercialization
Key Metrics to Watch
- Quarterly revenue trajectory and path to breakeven operating income
- Monthly cash burn rate and updated cash runway projections
- Operating cash flow trend and evidence of approaching cash flow positivity
Prokidney Corp.. (PROK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.13x current ratio provides a solid financial cushion.
PROK Profit Margin, ROE & Profitability Analysis
PROK vs Healthcare Sector: How Prokidney Corp.. Compares
How Prokidney Corp.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prokidney Corp.. Stock Overvalued? PROK Valuation Analysis 2026
Based on fundamental analysis, Prokidney Corp.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prokidney Corp.. Balance Sheet: PROK Debt, Cash & Liquidity
PROK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prokidney Corp..'s revenue has grown significantly by 1,075% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
PROK Revenue Growth, EPS Growth & YoY Performance
PROK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$16.5M | N/A |
| Q2 2025 | N/A | -$12.5M | N/A |
| Q1 2025 | N/A | -$9.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prokidney Corp.. Dividends, Buybacks & Capital Allocation
PROK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prokidney Corp.. (CIK: 0001850270)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PROK
What is the AI rating for PROK?
Prokidney Corp.. (PROK) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PROK's key strengths?
Claude: Strong revenue growth rate (+1075% YoY, though from minimal base). Net loss improving substantially YoY (+54.5% improvement).
What are the risks of investing in PROK?
Claude: Negative stockholders' equity indicating technical insolvency on book value basis. Catastrophic burn rate: -$135.3M free cash flow annually with <1 year cash runway.
What is PROK's revenue and growth?
Prokidney Corp.. reported revenue of $893.0K.
Does PROK pay dividends?
Prokidney Corp.. does not currently pay dividends.
Where can I find PROK SEC filings?
Official SEC filings for Prokidney Corp.. (CIK: 0001850270) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PROK's EPS?
Prokidney Corp.. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PROK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Prokidney Corp.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PROK stock overvalued or undervalued?
Valuation metrics for PROK: ROE of N/A (sector avg: 15%), net margin of -7,725.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PROK stock in 2026?
Our dual AI analysis gives Prokidney Corp.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PROK's free cash flow?
Prokidney Corp..'s operating cash flow is $-120.1M, with capital expenditures of $15.2M. FCF margin is -15,152.6%.
How does PROK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,725.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 9.13 (avg: 2).